There is considerable evidence that many disease are associated with endothelial dysfunction and reduced nitric oxide production such as hypertension, obesity, dyslipidemias, diabetes, heart failure, atherosclerosis. Notably these conditions are also characterized by alteration in the adrenergic tone.
Introduction
The endothelium controls several vascular functions, including vasculature tone and permeability, thrombosis, hemostasis and angiogenesis [1] [2] [3] [4] . It is noteworthy that all these functions can be regulated by the activation of receptors and often the same receptor can activate multiple endothelial functions. The adrenergic system is the major regulator of cardiac and vascular function and of endothelial vasorelaxation by means of  and  adrenergic receptors activation. The adrenergic receptors (ARs) are part of a large family of G protein coupled receptors (GPCR) which mediate the functional effects of catecholamines like epinephrine and norepinephrine. The ARs family includes three  ( 1 ,  2 ,  3 ), three  1 ( 1A ,  1B ,  1D ) and three  2 ( 2A ,  2B ,  2C ) receptor subtypes. These receptors actively participate to the release of nitric oxide (NO) in order to regulate endothelial function 5 . NO plays a crucial role in endothelium homeostasis, with important vasodilatory, anti-thrombotic and anti-atherogenic properties. NO mediates most of the endothelial functions: it has been invoked as a mechanism in vasorelaxation, endothelium permeability and neoangiogenesis 3 . NO in the endothelium is constitutively produced by the endothelial NO synthase, eNOS 6 . This latter is then further activated through calcium levels 7 and phosphorylation of various serine residues by a number of protein kinases 8, 9 . Indeed, it has been demonstrated that NO is activated by means of the PI3K pathway in response to the stimulation of tyrosine kinase 10, 11 .
The impaired ability of vascular endothelium to stimulate vasodilation is referred to as "Endothelial Dysfunction" and the major cause is the decreased bioavailability of NO in different conditions which can be due to various mechanisms: reduced eNOS expression, altered NO production and increased NO catabolism. Endothelial dysfunction plays a key role in the development of cardiovascular disease such as hypertension, type 2 diabetes and heart failure. The identification of the underlying pathogenic mechanisms will lead to the discovery of newer and more potent tools to 
 1 AR and angiogenesis
Neo-angiogenesis has long been known to be a highly ordered multistep molecular process under tight regulation by endothelial cells 15 and closely associated with endothelial cell proliferation and migration and to the capability of these cells to modulate the levels of VEGF, the most important cytokine system involved in the formation of new vessels 16 . A series of biological, chemical, hormonal effectors can interfere with this process. Several data support the notion that α 1 -adrenergic receptor should also be ranked among these agents. Indeed, it has been demonstrated that the  1A -and the  1B -AR subtypes but not the  1D subtype are expressed in cultured rat aorta endothelial cells. The activation of these  1 -AR in endothelial cells provide a negative regulation of angiogenesis 17 . Indeed, pharmacological antagonism of  1 -AR in endothelial cells from WKY rats by doxazosin enhanced, while stimulation of these adrenergic receptors with phenylephrine, inhibited endothelial mechanisms of angiogenesis such as cell proliferation and DNA synthesis, ERK and retinoblastoma protein (Rb) phosphorylation, cell migration and tubule formation 17 . A similar phenotype can be observed in vivo, since an increased  1 -adrenergic receptor density in the ischaemic hindlimb, compared to non-ischaemic hindlimb, suggested an enhanced  1 -adrenergic receptor tone in the ischaemic tissue. Treatment with doxazosin did not alter systemic blood pressure but enhanced neo-angiogenesis in the ischaemic hindlimb 17 .
Università degli Studi di Salerno . This appears to hold true through experimental models (rat or man) and vascular districts (see Figure 1 ). 
 2 AR and Nitric oxide
For years it has been given for granted that vascular β 2 AR mediate adrenergic vasorelaxation through direct activation of vascular smooth muscle cells 56 . However, recent data challenge this vision, and show that β 2 AR-dependent vasorelaxation is mediated at least in part, by endothelium through nitric oxide (NO) dependent processes 10 . We have recently demonstrated that the β 2 AR are expressed on endothelial cells (EC) and their stimulation causes endothelial nitric oxide synthase (eNOS) activation 57 . In particular,   AR couple to eNOS and induce NO dependent vasodilation 57 .
The mechanism of eNOS activation following β 2 AR stimulation is known to be AKT dependent 58 .
Indeed, the activity of eNOS is regulated by both a calcium/calmodulin dependent fashion 59 and AKT dependent eNOS phosphorylation in Ser 1177 8, [60] [61] [62] [63] . AKT is primarily activated in response to stimulation of transmembrane receptors with intrinsic tyrosine kinase activity or indirectly coupled to tyrosine kinases or to seven transmembrane G protein-coupled receptor 11, 61, 64 . Therefore AKT acts as integrator of different signal transduction pathways converging on eNOS, including endothelial β 2 AR receptor 9, 58, 62, 63, 65 .
3.

 2 AR and angiogenesis
In the endothelium ARs control other important endothelial functions like angiogenesis, that is tightly associated to endothelial cell migration and proliferation 57, 65, 66 . We demonstrated that   AR stimulation with ISO and the overexpression of   AR increases endothelial cell proliferation.
Moreover,   AR stimulation induces ERK phosphorylation and the MEKK inhibitor, U0126, inhibits   AR induced cell proliferation 66 suggesting that   AR dependent cell proliferation is dependent on ERK activation. We studied post-ischaemic angiogenesis in the hindlimb (HL) of β 2 AR knock-out mice (β 2 AR-/-) in vivo and explored possible molecular mechanisms in vitro.
Angiogenesis was severely impaired in β 2 AR-/-mice subjected to femoral artery resection, but was restored by gene therapy with ADβ 2 AR. The proangiogenic responses to a variety of stimuli were impaired in β 2 AR-/-EC in vitro 17 . Moreover, removal of β 2 ARs impaired the activation of NFκB, a transcription factor that promotes angiogenesis; ISO did not induce NFκB activation in β 2 AR(-/-) EC 17 . ADβ 2 AR administration restored β 2 AR membrane density and reinstated the NFκB response to ISO 17 . These results suggest that β 2 ARs control angiogenesis through the tight regulation of nuclear transcriptional activity.
 
5.
 1 ARand  2 AR differently regulate neo-angiogenesis α 1 -and β 2 -adrenergic receptors mediate opposite effects on neo-angiogenesis, comparable to their regulation of the vascular tone. In particular, the α 1 -AR is inhibitory, whereas the β 2 -AR is stimulant to neo-angiogenesis. Interestingly, in ischaemia, the α 1 -AR are upregulated, thus causing a predominance of α 1 -adrenergic receptor signalling over that of β 2 -AR, which is downregulated.
Furthermore, in conditions such as hypertension, where the α 1 -AR tone is higher than that of the β 2 -AR, there is also an impairment in neo-angiogenesis 66, 67 . It is interesting to note that in the ischaemic hindlimb, α 1 -AR blockade resulted in a normalization of β 2 -AR density together with improved neo-angiogenesis. α 1 -AR upregulation, in particular, might be a regulatory mechanism aimed at preventing excessive angiogenesis. This upregulation might be triggered by ischaemia, through regulatory sequences within the gene promoter, which have been demonstrated for both the α 1A -and α 1B -adrenergic receptor 68, 69 .
6.
 3 adrenergic receptors
In rat thoracic aorta, Trochu showed that  3 AR are mainly located on endothelial cells and act in conjunction with  1 AR and  2 AR to mediate relaxation through activation of NO synthase pathway and subsequent increase in tissue cyclic GMP content and is reduced by endothelium removal or in presence of L-NMMA 70 . This  3 AR mediated aorta relaxation seems to be independent of G i proteins stimulation, since the blockage of G i protein by PTX does not modify  3 AR agonists induced relaxation. On the contrary, selective potassium channels blockers of K (Ca), K (ATP) and K (v) decreased  3 AR agonists induced relaxation. So it appears that this effect results from the activation of several potassium channels, K (Ca), K (ATP) and K (v) 71 .
Pathological implications
It was reported that noradrenaline-induced release of nitric oxide is enhanced in mineralcorticoid hypertension 72 indicating that  2 AR may play an important role in the regulation of vascular tone not only in physiological but also in pathological conditions. The implications of impaired βAR signalling in the pathophysiology of several cardiovascular disorders has been studied in animals and humans. Data from these studies indicate that changes in βAR function are induced by heart failure 73, 74 and hypertension 75, 76 . Moreover, alteration in βAR function were found also with physiological aging 77, 78 , due to receptor downregulation and desensitization. Exercise restored the impaired signalling and AR dependent vasorelaxation 79 . We and others have observed that impaired βAR signalling may account for dysfunctional βAR vasorelaxation in hypertension. In this condition, β 2 AR overexpression in hypertensive rat carotids corrects impaired vasorelaxation to AR stimulation to levels similar to those seen in normotensive rats 57 . We proved that impaired endothelium dependent vasorelaxation in spontaneously hypertensive rats (SHR) can be corrected by increasing the signal transduction pathways leading to nitric oxide synthase activation 80 . In particular, since eNOS is activated in response to phosphorylation by AKT and impaired AKT activity is involved in endothelial dysfunction, AKT overexpression should result in the correction of impaired phenotype. Indeed, insulin and ISO cause AKT membrane localization and this subcellular localization is impaired in SHR. AKT overexpression, through means of adenovirus mediated AKT gene transfer to the endothelium, increases the amount of AKT localized to the membrane and corrects impaired NO release and endothelium dependent vasodilation to agonists of both the GPCR and tyrosine kinase (TK) dependent pathways.
Conclusions
In the last years great advances have been made in the study of adrenergic receptors signaling and function in the endothelium also thanks to the development of new technologies. Indeed, genetic mouse models have significantly improved our understanding of the mechanisms of action of specific drugs in vivo. The ability to induce transgene expression at defined times or in defined tissues is an important goal as well as the ability to induce or repress the expression of endogenous genes in a developmental or tissue specific fashion. Indeed, deletion of the genes encoding for adrenergic receptor subtypeshas helped to identify the specific subtypes whichmediate in vivo effects of specific drugs. Thus, the combination of molecular biological, genetic, and pharmacological techniques greatly facilitates our understanding of adrenergic receptor function in vivo, and in turn leads to more effective and specific therapeutic treatment in humans. 
